Differential Receipt of Sentinel Lymph Node Biopsy Within Practice-based Research Networks by Meyer, Anne Marie et al.
Differential receipt of sentinel lymph node biopsy within
practice-based research networks
Anne-Marie Meyer1,2, Katherine E. Reeder-Hayes1,3, Huan Liu1, Stephanie B. Wheeler1,4,
Dolly Penn5, Bryan J. Weiner2,4, and William R. Carpenter1,2,4
1UNC-Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
2Cecil G. Sheps Center for Health Services Research, UNC, Chapel Hill, NC, USA
3Department of Hematology/Oncology, School of Medicine, UNC, Chapel Hill, NC, USA
4Department of Health Policy and Management, Gillings School of Global Public Health,
University of North Carolina, Chapel Hill, NC, USA
5Department of Surgery, School of Medicine, UNC, Chapel Hill, NC, USA
Abstract
Background—Provider-based research networks (PBRNs) are promising for accelerating not
only research, but also dissemination of research-based evidence into broader community practice.
Sentinel lymph node biopsy (SLNB) is an innovation in breast cancer care associated with
equivalent survival and lower morbidity, as compared to standard axillary lymph node dissection.
We examined the diffusion of SLNB into practice and whether affiliation with the Community
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Clinical Oncology Program (CCOP), a cancer-focused PBRN, was associated with more rapid
uptake of SLNB.
Research Design—Surveillance Epidemiology and End Results(SEER)-Medicare data were
used to study women diagnosed with stage I or II breast cancer in the years 2000 to 2005 and
undergoing breast conserving surgery with axillary staging (n=6,226). The primary outcome was
undergoing SLNB. CCOP affiliation of the surgical physician was ascertained from NCI records.
Multivariable generalized linear modeling with generalized estimating equations was used to
measure association between CCOP exposure and undergoing SLNB, controlling for potential
confounders.
Results—Women treated by a CCOP physician had significantly higher odds of receiving SLNB
compared to women treated by a non-CCOP physician (OR 2.68; 95% CI 1.35, 5.34). The
magnitude of this association was larger than that observed among patients treated by physicians
operating in medical school-affiliated hospitals (OR 1.76; 95% CI 1.30–2.39).
Conclusion—Women treated by CCOP-affiliated physicians were more likely to undergo SLNB
irrespective of the hospital’s medical school affiliation, suggesting that the CCOP PBRN may play
a role in the rapid adoption of research-based innovation in community practice.
Keywords
Epidemiology; Breast Cancer; Practice-based research networks (PBRN); Community Clinical
Oncology Program (CCOP); Sentinel Lymph Node Biopsy; SEER-Medicare
Introduction
The rapidly evolving field of cancer care demands efficient dissemination of treatment
innovations. Delays in the translation of research into practice deny patients novel care that
would likely produce a more favorable outcome.[1–3] One potential mechanism to
accelerate the translation of cancer research into practice is through provider-based research
networks (PBRNs). Embraced by the National Institutes of Health (NIH) in the Roadmap,
PBRNs are research partnerships between academic investigators and community-based
practitioners that expedite research by providing greater access to larger, more diverse
populations.[4, 5] PBRNs are also believed to facilitate the dissemination of innovations to
these populations through enhanced communication and engagement through these research
partnerships.[6–8] While PBRNs are promising in this regard, there is limited empirical
evidence characterizing their role in dissemination of innovative clinical practice.
To better understand the role of PBRNs in the innovation of cancer care, we examined
whether diffusion of sentinel lymph node biopsy (SLNB) into practice was associated with a
cancer-focused PBRN. SLNB is an innovation in the surgical approach to early stage breast
cancer that has been used as an indicator of innovative breast cancer care.[9–11] Before
SLNB was introduced, the more invasive axillary lymph node dissection (ALND) was the
standard of care.[9, 12, 13] Research demonstrated that SLNB is associated with similar
survival benefit to ALND, yet has much less morbidity. Several health system factors have
been associated with increased probability of a woman having SLNB, while at the same time
there is evidence of disparities within some populations.[14, 15]
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Our study examines undergoing a SLNB procedure in the context of the National Cancer
Institute’s (NCI’s) Community Clinical Oncology Program (CCOP), a cancer-focused
PBRN that has played a substantial role in the nation’s cancer clinical research.[8] Founded
in 1983, this network links community-based physicians with academic investigators with
the goal of improving cancer care quality in local communities through increased physician
and patient participation in research and more rapid implementation of evidence-based
research findings into clinical practice.[8] Physician participation in research and associated
information networks have been associated with significant differences in patterns of breast
cancer care.[16–18] By contrast, there is conflicting evidence regarding the association
between hospital teaching status and its role in innovative breast cancer treatment.[14, 18]
There is also limited evidence distinguishing the roles and interactions between physician
participation and hospital participation in cancer-focused PBRNs.
Accordingly, this study examined the association between CCOP affiliation and innovation
adoption, and the roles of physician participation in cancer-focused PBRNs in the context of
other hospital-level factors associated with teaching and research. By doing so, it contributes
important evidence to a growing body of literature empirically supporting the association
between the CCOP PBRN and accelerated translation of evidence-based findings into
practice. It also helps clarify our understanding of the conduits for communication and
mechanisms through which such translation may occur.
Methods
Data
A retrospective cohort of breast cancer patients was identified from the Surveillance
Epidemiology and End Results (SEER)-Medicare linked data.[19] The SEER-Medicare
program is a collaborative effort between NCI and the Centers for Medicare and Medicaid
Services (CMS). The SEER data are drawn from 17 population-based cancer registries that
represent approximately 28 percent of the US cancer population. The data are comprised of
patient demographic information and detailed cancer information including stage, grade, and
tumor receptor status. The vast majority of Americans 65 years old and older participate in
Medicare (97%), and their claims data capture their health services utilization including
information on comorbid health conditions. Linked together, SEER-Medicare data have
supported numerous published studies examining the relationships between diagnoses,
treatments, and outcomes through an entire course of care.[20] Our study further enriched
these data to include information on the CCOP-affiliation of physicians and hospitals from
the NCI CCOP Program. The CCOP data were obtained directly from the NCI CCOP
program annual reports. The unique physician identification number (UPIN) for
participating CCOP physicians were abstracted directly from these data.
Patient Selection
The study cohort included women who were diagnosed with stage I or II breast cancer as
their first and only primary tumor between 2000 and 2005 and who received breast
conserving surgery. We limited the study to women receiving breast conserving surgery
because there is some ambiguity and potential for greater misclassification within
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mastectomy codes with regard to lymph node procedures compared to breast conserving
surgery codes. Specifically, modified radical mastectomy (MRM) includes ALND, with no
separate code for the lymph node procedure. To control for comorbidities before diagnosis
and capture complete treatment information, we restricted the analysis to women age 66 and
older who had complete Medicare data 12 months before diagnosis until 12 months after
diagnosis. Women were also excluded if they received no treatment for breast cancer from
30 days pre-diagnosis through 12 months post-diagnosis.
Main outcome and exposure
Undergoing a SLNB procedure was the primary outcome of interest. Both SLNB and ALND
were identified using International Classification of Diseases version 9 (ICD-9) Procedure
codes, Current Procedural Terminology (CPT) codes, or Healthcare Common Procedure
Coding System (HCPCS) codes from Medicare claims within 30 days of breast conserving
surgery (BCS). Patients were categorized as undergoing SLNB if their scope of regional
lymph node surgery in Medicare procedure claims indicated sentinel node removal or dye
injection for identification of sentinel node. Patients were categorized as undergoing primary
ALND if their procedure codes indicated axillary lymphadenectomy or if none of the criteria
for SLNB were met (Appendix A). Patients who had SLNB followed by ALND were
categorized as having undergone SLNB.
A patient was defined as a CCOP patient by isolating the unique UPIN on the Medicare
claims for breast surgery. Of the 4,525 unique UPINs associated with the patients receiving
surgery in our cohort, 1.9% of them (84 providers serving 874 patients) were CCOP-
affiliated UPINs. Patients were considered CCOP patients if the UPIN on the breast surgery
claim was that of a UPIN affiliated with the NCI CCOP program during the study period.
We chose this more conservative CCOP exposure definition because we hypothesized the
CCOP effect would occur via the provider most influential in surgical decision making. We
also performed sensitivity analyses testing other definitions of CCOP exposure, including
measure of proportion (percent of all claims associated with a CCOP physician), and
comprehensive binary measure (any claim within the treatment window associated with a
CCOP physician).
Covariates
Covariates selection reflected person-level, physician-level, and organization-level factors
believed to be associated with treatment selection informed by our previous research and
other published literature. [21–24] Person-level characteristics included age at diagnosis,
race, and marital status at diagnosis [25–27]. Socio-demographic information included a
patient-level measure of low income status defined by an application and approval within
each state of Medicaid eligibility to support health care costs for the patient (State Buy-In).
[28] Also included was a measure of the educational level in the patient’s home census tract
measured in quartiles within each registry and combined across registries following previous
methodology.[29] Tumor information included stage, grade, and estrogen receptor status.
Stage was defined according to the American Joint Committee on Cancer TNM staging
system 3rd and 6th editions (2000–2003 and 2004–2005 cases, respectively). Medicare
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claims data were used to calculate a breast cancer specific measure of comorbidities using
the NCI combined comorbidity index [30].
To control for the surgical volume of physicians (e.g., high-volume surgeons), we created a
study specific measure of total breast procedures per UPIN using the claims from our patient
cohort and included this as a continuous variable. Hospital organization-level measures were
included to examine the other mechanisms through which there may be differential
innovation diffusion. Using the SEER-Medicare Hospital file we included hospital-level
measures of medical school affiliation, NCI cancer center designation, and the number of
beds. NCI cancer center is included as a binary variable (Yes, No) and we categorized the
number of hospital beds into quartiles. Each hospital’s medical school affiliation was
defined using a four-level variable in the Medicare hospital file which indicates degree of
hospital affiliation with a medical school. This was retained as a binary variable in the main
model where all levels of affiliation with a medical school (Major, Graduate or Limited)
were grouped and compared to the referent “unaffiliated.” Based on a priori hypotheses and
bivariate analyses, we also tested an interaction term between CCOP and medical school
affiliation.
Statistical Analysis
Bivariate analyses were conducted to examine crude associations among variables and
covariate independence. To calculate the odds of undergoing SLNB, we used a generalized
linear mixed model with maximum likelihood estimates based on Laplace approximation,
implemented by the GLIMMIX procedure (logit link function) in SAS 9.2 (SAS, 2009).
This procedure uses random effects and takes into account the hierarchical clustering of
patients within physicians and physicians within hospitals when calculating estimates of
association between covariates. We tested the interaction terms between CCOP and medical
school affiliation. The interaction term was not statistically significant; therefore, we
concluded the effect of CCOP affiliation was not moderated by medical school affiliation.
To demonstrate diffusion of SLNB over the study period, figures were developed showing
the crude proportion of SLNB in each of the exposure groups.
Results
The study cohort comprised 17,177 women after applying all study inclusion criteria (Figure
1); the full characteristics of the study sample are described in Table 1. The vast majority of
women (95%) received care outside of CCOP-affiliated settings (“non-CCOP”) based on the
affiliation of the surgeon performing their nodal dissection. Of the 854 women who were
CCOP patients, 770 received SLNB. Consistent with an early-stage breast cancer cohort,
there was a greater proportion of stage I (67%), well-to-moderately differentiated (70%),
and estrogen receptor positive (77%) tumors. Women who saw a CCOP physician were
more likely to receive SLNB throughout the study period (Figure 2). From 2000 to 2005 the
proportion of women receiving SLNB increased to from 73% to 96% in the CCOP sample
and from 54% to 86% in the non-CCOP sample.
In multivariate models controlling physician and hospital clustering, the odds of undergoing
SLNB for women treated by a CCOP physician were nearly 2.7 times that of non-CCOP
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women (OR 2.68; 95%CI 1.35, 5.34) (Table 2). Smaller, but significant increases in odds of
having SLNB were also seen in women treated at a medical school-affiliated (OR 1.76;
95%CI 1.30, 2.39). In fact, the CCOP effect remained at the same magnitude and precision
in sensitivity analyses excluding these hospital variables (OR 5.10; 95%CI 2.58, 10.10)
(data not shown). An additional sensitivity analysis tested the contrasts in the estimates of a
four level-variable combining CCOP and medical school affiliation which provided even
more support that CCOP affiliation was independently associated with differential receipt of
treatment irrespective of hospital affiliation. (Tables 3 & 4)
Women with lower-stage disease and better-differentiated tumors were also more likely to
receive SLNB. However, significant racial, age and income disparities were evident in the
women undergoing SLNB. Women who were African American, over 80 years of age, and
with lower SES (as measured by Medicaid State-buy-in) were significantly less likely to
undergo SLNB (OR 0.71; 95% CI 0.52, 0.97 and OR 0.67; 95% CI 0.56, 0.82, and OR 0.70;
95% CI 0.55, 0.89 respectively).
Discussion
Our study found a significant association between physician CCOP-affiliation and women’s
likelihood of having SLNB as a part of breast cancer surgery during the early adoption of
this innovative procedure. We also found that the influence of CCOP physicians appeared to
be more strongly associated with a patient having SLNB than the hospital affiliation with a
medical school. This finding may challenge the perception that patients must travel to an
academic medical center to receive innovative cancer care. It also indicates that within
surgical treatment of breast cancer the CCOP initiative may be achieving its mission of
promoting adoption of treatment innovations. Previously, we have published on an
association between CCOP affiliation and innovative chemotherapeutic treatment in colon
cancer.[22] Together, these studies suggest that the CCOP PBRN is associated with
innovative cancer care in community settings.
There are several possible reasons for this observed association. CCOP physicians may
benefit from networks and communication pathways associated with research, which may be
distinct from their clinical care networks. These research networks may facilitate access to
cutting-edge information in both research and practice before the information is more
broadly disseminated to the clinical community. Related to this, engaging in research may
foster a sense of ownership and trust of the information, as well as provide a more controlled
setting through which to gain experience with the innovation and become comfortable in
using it.
We examined other links to research networks as well, namely, treating hospitals’ affiliation
with medical schools, which have been the hubs of clinical research since prior to the
development of provider-based research networks. Not surprisingly, patients treated at a
medical school-affiliated hospital were more likely to undergo SLNB than those treated
elsewhere. This being said, the association with innovation adoption seen through CCOP
affiliation was persistently stronger than that observed for medical school affiliation. Several
sensitivity tests examined multiple forms of these two measures and their interaction, and
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the observed relationships were consistent and independent. This result is plausible and
important for several reasons. Among them, the independence of the measures strengthens
our confidence in the study approach and findings, as the CCOP program was developed to
operate outside of academic medical centers; so, the two measures should be independent by
programmatic design. It also suggests the existence and the relevance of multiple
communication pathways for innovation diffusion, which merits further examination.
SLNB adoption in this population does not appear to be driven by clinical trial accrual
alone. While we do not have data on whether patients in our sample were recruited into a
SLNB clinical trial, we did have data from the NCI which indicated trial participation by
CCOP location. Using these data, we were able to estimate that almost 40% of the patients
were seen in CCOPs which were not participating in any of the SLNB trials. Additionally,
the total number of patients in these trials was a small fraction of those in our CCOP study
sample. Finally, if there were a trial-driven adoption benefit, one would expect it to attenuate
after the close of the trials; however, this study yielded utilization rates that do not converge,
and instead appear to plateau, with CCOPs demonstrating persistently greater use of the new
procedure.
This study has several strengths. Among them, our cohort represents a large, population-
based sample of breast cancer patients in the United States. The SEER-Medicare data allow
for an extended period of observation during adoption of innovative treatment for breast
cancer. With the addition of the NCI CCOP information these data represent a novel
opportunity to examine physician and hospital-level influences on dissemination of
treatment innovations in cancer care. Building off of previous research, we control for
multiple organizational determinants and other important confounders in order to isolate the
associations with the main exposure. This study also includes a hierarchical design to
control for patient clustering within physicans and hospitals.
Despite these many unique strengths, our study also has several limitations. Among them, it
is observational and the retrospective cohort is restricted to patients with complete follow-up
information. The outcome, defined through claims, may be missing detailed clinical
information such as HER2 status. This missing contextual patient information may provide
important context regarding physican or patient intent and decision-making. The relative
number of patients exposed to CCOPs was very small, and the data do not include a patient-
level marker of clinical trial participation. However, we have attempted to address these
issues through sensitivity analyses, by examining CCOP participation in the relevant SLNB
trials, and by accounting for the hierarchical structure of the data. Finally, our measure of
CCOP affiliation may incompletely characterize physicians in these data. We do not have a
record of when the physicians join or exit the CCOP program and are unable to create time-
varying CCOP exposure. Secondly, there are different levels of practice affiliation and
participation within the CCOP which we are unable to control for at the physician level[31].
Moreover, arguments may be made that there may be an element of self-selection of
physicians into a CCOP which would mediate rather than confound the observed
association. Specifically, CCOP practices may attract and retain physicians who are more
likely than others to follow the development of new medical technologies, and identify and
adopt them regardless of their affiliation with the CCOP program. The measure may also be
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a marker for other physician-level factors outside of the CCOP program, such as experience
or training. These are plausable, and the exploration of possible mediation by the CCOP
program or physican characteristics are important next steps for this research area.
Regardless of the exact mechanism, it is clear that patients treated by CCOP-affiliated
physicians were more likely to undergo this state-of-the-art therapy than patients treated
elsewhere at the time the innovation was entering clinical practice. While it was beyond the
scope of the current study, future research could also examine CCOP affiliation and the
differential persistence of disparities associated with race, age, and wealth illuminated by
this analysis. Additionally, research that includes more detailed physician and organizational
level variables could help untangle and identify more specific system attributes that promote
treatment innovation. Other next steps for this area would be to incorporate these additional
variables while applying more sophisticated statistical models designed for causal inference.
This study represents a unique attempt to disentangle different effects of provider and
hospital affiliation in the context of innovative breast cancer care using secondary data. Our
approach of combining existing (SEER-Medicare) data with unique additional information
on individual providers allows us to better understand the relationships between factors that
affect adoption of innovative in treatments at the institution, provider, and patient-level.
Understanding the relative contribution of the different health system mechanisms will help
to target interventions more effectively and influence adoption of innovative cancer care.
Our findings suggest that a PBRN program, such as the CCOP, may be a good model for the
dissemination of innovative cancer treatments into practice settings beyond large academic
institutions.
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List of ICD and CPT codes defining outcomes
ICD-9-CM Procedure codes Procedure CPT codes
Breast Conservation Surgery
(BCS)
85.20 85.21 85.22 85.23 85.20
Mastectomy 85.41 85.42 85.43 85.44 85.4585.46 85.47
85.48 85.49
Sentinel Lymph Node Biopsy
(SLNB)
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*Study period is from 12 months prior to diagnosis to 12 months after diagnosis or Medicare
record of death, whichever comes first.
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Table 2
Adjusted Odds Ratios for SLNB in women receiving breast-conserving surgery in SEER-Medicare, 2000–
2005 (n=17,177)
Adjusted Odds Ratio 95% CI
Race (ref.= Caucasian American) African American 0.71* (0.52–0.97)
Age (ref.= 65–69 yr) 70–74 yr 0.98 (0.82–1.16)
75–79 yr 0.88 (0.74–1.06)
80+ yr 0.67** (0.56–0.82)
Marital status (ref.= Married) Unmarried or Unknown 0.95 (0.83–1.09)
Dual eligibility for Medicaid (ref.= No) Yes 0.70** (0.55–0.89)
NCI comorbidity score (ref.= 1+) 0 1.04 (0.91–1.19)
Tumor stage (ref.= Stage IIB or NOS) Stage I 1.84** (1.46–2.31)
Stage IIA 1.36* (1.06–1.74)
Tumor grade (ref.= Poorly differentiated and Undifferentiated) Well differentiated 1.57** (1.29–1.91)
Moderately differentiated 1.28** (1.09–1.51)
Unknown, not assessed 1.27 (0.98–1.64)
Estrogen receptor status (ref.= Positive) Unknown 0.89 (0.72–1.11)
Negative 0.94 (0.76–1.17)









New Mexico 0.74 (0.27–2.05)
Seattle 5.57** (2.80–11.11)
Utah 0.64 (0.30–1.40)
Atlanta and Rural Georgia 1.12 (0.49–2.58)
All California 0.51* (0.31–0.83)
Kentucky 0.99 (0.50–1.98)
Louisiana 0.62 (0.31–1.22)
Census group percent of non-high school graduates in quartiles
(ref.= Quartile 1)
Quartile 2: 25%–<50% 0.86 (0.73–1.03)
Quartile 3: 50%–<75% 0.81* (0.67–0.99)
Quartile 4: >=75% 0.75** (0.61–0.92)
Hospital total bed size (ref.= Quartile 1) Quartile 2: 25%–<50% 1.34 (0.89–2.03)
Quartile 3: 50%–<75% 1.99** (1.26–3.16)
Quartile 4: >=75% 1.90* (1.17–3.06)
NCI cancer center designated 2.87* (1.19–6.94)
Medical school affiliation (Major/Grad/Limited vs. Unaffiliated) 1.76** (1.30–2.39)
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Adjusted Odds Ratio 95% CI
Physician surgical volume 1.04** (1.03–1.06)
CCOP physician 2.68** (1.35–5.34)
Abbreviations: CCOP, Community Clinical Oncology Program; CI, confidence interval; NCI, National Cancer Institute; NOS, not otherwise
specified; SEER, Surveillance Epidemiology and End Results
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Table 3
Multivariate adjusted effect estimates for combined variable measuring CCOP and Medical school affiliation.
Exposure Levels Adjusted Odds Ratio 95% CI
Combined Medical School Affiliation and CCOP (ref. = No
affiliation, non-CCOP)
(1) Major/Grad/Limited, CCOP 3.95** (1.61–9.71)
(2) No-affiliation, CCOP 3.23** (1.43–7.31)
(3) Major/Grad/Limited, non-CCOP 1.76** (1.30–2.40)
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Table 4
Contrast test for differences between effect estimates combining CCOP and Medical school affiliation.
Contrast Adjusted Odds Ratio 95% CI Pr>ChiSq
(1) vs (3) 2.24 (0.95–5.26) 0.0671
(1) vs (2) 1.22 (0.43–3.49) 0.7056
(2) vs (3) 1.83 (0.80–4.18) 0.1545
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